Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics Inc (NQ: FULC )

7.170 +0.020 (+0.28%)
Streaming Delayed Price Updated: 12:04 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 142,989
Open 7.150
Bid (Size) 7.160 (4)
Ask (Size) 7.170 (12)
Prev. Close 7.150
Today's Range 6.963 - 7.210
52wk Range 2.420 - 13.70
Shares Outstanding 61,758,994
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks. 
Via InvestorPlace
Fulcrum Therapeutics Inc. (NASDAQ: FULC) is a Stock Spotlight on 4/12
Via Investor Brand Network

Performance

YTD
-0.55%
-0.55%
1 Month
-29.15%
-29.15%
3 Month
-1.51%
-1.51%
6 Month
+95.37%
+95.37%
1 Year
+191.46%
+191.46%

More News

Read More
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Inc. (NASDAQ: FULC) is a Stock Spotlight on 3/6
Via Investor Brand Network
Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Earnings Scheduled For February 27, 2024
Via Benzinga
Earnings Preview: Fulcrum Therapeutics
Via Benzinga
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Preview: Fulcrum Therapeutics's Earnings
Via Benzinga
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
MicroMarvet - Fulcrum Therapeutics - Confusing Projections And Recommendation
Via Talk Markets
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Inc. (NASDAQ: FULC) Near the Top of Equities by Percentage Gain on 11/7
Via Investor Brand Network
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.